%	O
%	O
TITLE	O

Does	O
HPV	O
type	O
affect	O
outcome	O
in	O
oropharyngeal	O
cancer	O
?	O

%	O
%	O
ABSTRACT	O

An	O
epidemic	O
of	O
human	O
papillomavirus	O
(	O
HPV	O
)	O
-	O
related	O
oropharyngeal	O
squamous	O
cell	O
cancer	O
(	O
OPSCC	O
)	O
has	O
been	O
reported	O
worldwide	O
largely	O
due	O
to	O
oral	O
infection	O
with	O
HPV	O
type	O
-	O
16	O
,	O
which	O
is	O
responsible	O
for	O
approximately	O
90	O
%	O
of	O
HPV	O
-	O
positive	O
cases	O
.	O

The	O
purpose	O
of	O
this	O
study	O
was	O
to	O
determine	O
the	O
rate	O
of	O
HPV	O
-	O
positive	O
oropharyngeal	O
cancer	O
in	O
Southwestern	B-Study_Location
Ontario	I-Study_Location
,	O
Canada	B-Study_Location
.	O
A	O
retrospective	O
search	O
identified	O
ninety	B-Study_Cohort
-	I-Study_Cohort
five	I-Study_Cohort
patients	I-Study_Cohort
diagnosed	I-Study_Cohort
with	I-Study_Cohort
OPSCC	I-Study_Cohort
.	I-Study_Cohort

Pre	O
-	O
treatment	O
biopsy	B-HPV_Sample_Type
specimens	I-HPV_Sample_Type
were	O
tested	O
for	O
p16	B-HPV_Lab_Technique
expression	I-HPV_Lab_Technique
using	I-HPV_Lab_Technique
immunohistochemistry	I-HPV_Lab_Technique
and	O
for	O
HPV	O
-	O
16	O
,	O
HPV	O
-	O
18	O
and	O
other	O
high	O
-	O
risk	O
subtypes	O
,	O
including	O
31	O
,	O
33	O
,	O
35	O
,	O
39	O
,	O
45	O
,	O
51	O
,	O
52	O
,	O
56	O
,	O
58	O
,	O
59	O
,	O
67	O
,	O
68	O
,	O
by	O
real	B-HPV_Lab_Technique
-	I-HPV_Lab_Technique
time	I-HPV_Lab_Technique
qPCR	I-HPV_Lab_Technique
.	I-HPV_Lab_Technique
Fifty	O
-	O
nine	O
tumours	O
(	O
62	O
%	O
)	O
were	O
positive	O
for	O
p16	O
expression	O
and	O
fifty	O
(	O
53	O
%	O
)	O
were	O
positive	O
for	O
known	O
high	O
-	O
risk	O
HPV	O
types	O
.	O

Of	O
the	O
latter	O
,	O
45	O
tumors	O
(	O
90	O
%	O
)	O
were	O
identified	O
as	O
HPV	O
-	O
16	O
positive	O
,	O
and	O
five	O
tumors	O
(	O
10	O
%	O
)	O
were	O
positive	O
for	O
other	O
high	O
-	O
risk	O
HPV	O
types	O
(	O
HPV	O
-	O
18	O
(	O
2	O
)	O
,	O
HPV	O
-	O
67	O
(	O
2	O
)	O
,	O
HPV	O
-	O
33	O
(	O
1	O
)	O
)	O
.	O

HPV	O
status	O
by	O
qPCR	B-HPV_Lab_Technique
and	O
p16	O
expression	O
were	O
extremely	O
tightly	O
correlated	O
(	O
p	O
<	O
0	O
.	O
001	O
,	O
Fishers	O
exact	O
test	O
)	O
.	O

Patients	O
with	O
HPV	O
-	O
positive	O
tumors	O
had	O
improved	O
3	O
-	O
year	O
overall	O
(	O
OS	O
)	O
and	O
disease	O
-	O
free	O
survival	O
(	O
DFS	O
)	O
compared	O
to	O
patients	O
with	O
HPV	O
-	O
negative	O
tumors	O
(	O
90	O
%	O
vs	O
65	O
%	O
,	O
p	O
=	O
0	O
.	O
001	O
;	O
and	O
85	O
%	O
vs	O
49	O
%	O
,	O
p	O
=	O
0	O
.	O
005	O
;	O
respectively	O
)	O
.	O

HPV	O
-	O
16	O
related	O
OPSCC	O
presented	O
with	O
cervical	O
metastases	O
more	O
frequently	O
than	O
other	O
high	O
-	O
risk	O
HPV	O
types	O
(	O
p	O
=	O
0	O
.	O
005	O
)	O
and	O
poorer	O
disease	O
-	O
free	O
survival	O
was	O
observed	O
,	O
although	O
this	O
was	O
not	O
statistically	O
significant	O
.	O
HPV	O
-	O
16	O
infection	O
is	O
responsible	O
for	O
a	O
significant	O
proportion	O
of	O
OPSCC	O
in	O
Southwestern	B-Study_Location
Ontario	I-Study_Location
.	I-Study_Location

Other	O
high	O
-	O
risk	O
subtypes	O
are	O
responsible	O
for	O
a	O
smaller	O
subset	O
of	O
OPSCC	O
that	O
present	O
less	O
frequently	O
with	O
cervical	O
metastases	O
and	O
may	O
have	O
a	O
different	O
prognosis	O
.	O

%	O
%	O
METHODS	O

Study	O
population	O

Study	O
approval	O
was	O
obtained	O
from	O
the	O
University	O
of	O
Western	B-Study_Location
Ontario	I-Study_Location
Research	O
Ethics	O
Board	O
.	O

A	O
retrospective	O
search	O
of	O
the	O
London	O
Regional	O
Cancer	O
Program	O
(	O
LRCP	O
)	O
database	O
was	O
performed	O
to	O
identify	O
patients	B-Study_Cohort
diagnosed	I-Study_Cohort
with	I-Study_Cohort
OPSCC	I-Study_Cohort
from	O
2003	B-Study_Time
to	I-Study_Time
2009	I-Study_Time
.	I-Study_Time

Patient	O
eligibility	O
required	O
:	O
1	O
)	O
a	O
histologically	O
confirmed	O
diagnosis	O
of	O
squa	O
-	O
mous	O
cell	O
carcinoma	O
,	O
2	O
)	O
no	O
prior	O
history	O
of	O
head	O
and	O
neck	O
cancer	O
,	O
and	O
3	O
)	O
the	O
availability	O
of	O
a	O
pre	O
-	O
treatment	O
primary	O
site	O
biopsy	B-HPV_Sample_Type
specimen	I-HPV_Sample_Type
for	O
analysis	O
.	O

Patient	O
data	O
was	O
extracted	O
from	O
a	O
retrospective	O
chart	O
review	O
,	O
which	O
included	O
age	O
at	O
diagnosis	O
,	O
use	O
of	O
tobacco	O
and	O
alcohol	O
,	O
AJCC	O
TNM	O
stage	O
,	O
treatment	O
regimen	O
,	O
and	O
post	O
-	O
treatment	O
follow	O
-	O
up	O
information	O
.	O

After	O
the	O
completion	O
of	O
cancer	O
therapy	O
,	O
patients	O
were	O
followed	O
closely	O
at	O
six	O
to	O
twelve	O
week	O
intervals	O
by	O
either	O
a	O
radiation	O
oncologist	O
or	O
head	O
and	O
neck	O
surgeon	O
.	O

Treat	O
-	O
ment	O
response	O
was	O
evaluated	O
by	O
physical	O
exam	O
as	O
well	O
as	O
computed	O
tomography	O
imaging	O
as	O
needed	O
.	O

Salvage	O
neck	O
dissection	O
was	O
undertaken	O
within	O
three	O
months	O
of	O
the	O
completion	O
of	O
radiation	O
treatment	O
if	O
evidence	O
of	O
re	O
-	O
sidual	O
adenopathy	O
was	O
present	O
radiographically	O
or	O
on	O
physical	O
exam	O
.	O

The	O
presence	O
of	O
neck	O
disease	O
more	O
than	O
three	O
months	O
after	O
diagnosis	O
was	O
considered	O
a	O
regional	O
persistence	O
.	O

Deparaffinization	O

The	O
formalin	O
fixed	O
paraffin	O
embedded	O
blocks	O
from	O
each	O
patient’s	O
primary	O
site	O
were	O
sectioned	O
(	O
5	O
μm	O
thick	O
)	O
and	O
mounted	O
on	O
slides	O
.	O

The	O
slides	O
were	O
then	O
deparaffinized	O
with	O
3	O
minute	O
washes	O
in	O
xylene	O
(	O
100	O
%	O
)	O
twice	O
,	O
followed	O
by	O
a	O
1	O
:	O
1	O
xylene	O
:	O
ethanol	O
mix	O
,	O
then	O
ethanol	O
(	O
100	O
%	O
)	O
twice	O
,	O
followed	O
by	O
single	O
washes	O
in	O
ethanol	O
at	O
95	O
%	O
,	O
70	O
%	O
and	O
50	O
%	O
.	O

Lastly	O
,	O
the	O
slides	O
were	O
washed	O
in	O
water	O
for	O
5	O
minutes	O
.	O

p16	B-HPV_Lab_Technique
immunohistochemistry	I-HPV_Lab_Technique

Citrate	O
buffer	O
was	O
applied	O
to	O
the	O
deparaffinized	O
slides	O
for	O
heat	O
induced	O
epitope	O
retrieval	O
for	O
30	O
minutes	O
,	O
followed	O
by	O
treatment	O
with	O
0	O
.	O
1	O
%	O
Triton	O
X	O
-	O
100	O
in	O
PBS	O
.	O

Endogen	O
-	O
ous	O
biotin	O
was	O
quenched	O
using	O
an	O
avidin	O
/	O
biotin	O
kit	O
(	O
Bio	O
-	O
care	O
Medical	O
,	O
Concord	O
CA	O
,	O
USA	O
)	O
and	O
the	O
endogenous	O

peroxidase	O
activity	O
was	O
blocked	O
by	O
H202	O
prior	O
to	O
primary	O
antibody	O
incubation	O
.	O

Specimens	B-HPV_Sample_Type
were	O
incubated	O
with	O
a	O
primary	O
mouse	O
monoclonal	O
antibody	O
against	O
human	O
p16	O
(	O
MTM	O
Laboratoris	O
,	O
Heidelberg	O
,	O
Germany	O
)	O
at	O
1	O
:	O
500	O
dilu	O
-	O
tion	O
.	O

The	O
Vectastain	O
ABC	O
kit	O
,	O
with	O
a	O
goat	O
anti	O
mouse	O
secondary	O
antibody	O
,	O
was	O
used	O
as	O
per	O
the	O
manufacturer’s	O
instructions	O
.	O

Antigen	O
detection	O
was	O
done	O
using	O
diamino	O
-	O
benzidine	O
chromogen	O
(	O
Biocare	O
Medical	O
,	O
Concord	O
,	O
CA	O
)	O
.	O

Tissues	B-HPV_Sample_Type
were	O
counterstained	O
with	O
Carazzi’s	O
hematoxylin	O
.	O

Immunohistochemistry	B-HPV_Lab_Technique
scoring	O
was	O
conducted	O
by	O
two	O
head	O
and	O
neck	O
pathologists	O
(	O
KK	O
and	O
BW	O
)	O
blinded	O
to	O
HPV	O
status	O
and	O
patient	O
outcome	O
.	O

Scoring	O
was	O
as	O
described	O
by	O
Begum	O
et	O
al	O
.	O
,	O
with	O
strong	O
and	O
diffuse	O
stain	O
-	O
ing	O
(	O
>	O
80	O
percent	O
of	O
tumour	O
cells	O
)	O
regarded	O
as	O
a	O
positive	O
result	O
,	O
and	O
negative	O
if	O
absent	O
or	O
focal	O

DNA	O
extraction	O

Deparaffinized	O
tissue	B-HPV_Sample_Type
was	O
scraped	O
into	O
a	O
1	O
.	O
5	O
ml	O
eppen	O
-	O
dorf	O
tube	O
containing	O
50–100	O
μl	O
(	O
depending	O
on	O
the	O
amount	O
of	O
tissue	B-HPV_Sample_Type
)	O
of	O
TE	O
and	O
proteinase	O
K	O
(	O
final	O
concen	O
-	O
tration	O
2	O
mg	O
/	O
ml	O
)	O
and	O
incubated	O
overnight	O
at	O
65°C	O
.	O

Fol	O
-	O
lowing	O
proteinase	O
K	O
treatment	O
,	O
the	O
samples	B-HPV_Sample_Type
were	O
heated	O
at	O
95°C	O
for	O
10	O
minutes	O
and	O
allowed	O
to	O
cool	O
to	O
room	O
temperature	O
.	O

0	O
.	O
2	O
μl	O
of	O
each	O
sample	B-HPV_Sample_Type
was	O
used	O
directly	O
in	O
the	O
qPCR	O
reactions	O
.	O

High	B-HPV_Lab_Technique
-	I-HPV_Lab_Technique
risk	I-HPV_Lab_Technique
HPV	I-HPV_Lab_Technique
detection	I-HPV_Lab_Technique
by	I-HPV_Lab_Technique
multiplex	I-HPV_Lab_Technique
qPCR	I-HPV_Lab_Technique

In	O
an	O
effort	O
to	O
screen	O
clinical	O
samples	B-HPV_Sample_Type
for	O
the	O
presence	O
of	O
human	O
papillomavirus	O
(	O
HPV	O
)	O
,	O
we	O
designed	O
a	O
multiplex	B-HPV_Lab_Technique
quantitative	I-HPV_Lab_Technique
PCR	I-HPV_Lab_Technique
to	O
identify	O
those	O
samples	B-HPV_Sample_Type
that	O
were	O
HPV	O
positive	O
and	O
to	O
confirm	O
the	O
HPV	O
type	O
in	O
the	O
posi	O
-	O
tive	O
samples	B-HPV_Sample_Type
.	O

We	O
designed	O
primer	O
/	O
probe	O
sets	O
(	O
Table	O
against	O
a	O
115	O
nucleotide	O
(	O
nt	O
)	O
fragment	O
within	O
exon	O
6	O
of	O
GAPDH	O
(	O
internal	O
control	O
)	O
,	O
a	O
110	O
nt	O
region	O
across	O
E6	O
-	O
E7	O
of	O
HPV	O
-	O
16	O
,	O
a	O
137	O
nt	O
fragment	O
across	O
the	O
HPV	O
-	O
18	O
E6	O
-	O
E7	O
region	O
,	O
and	O
a	O
100	O
nt	O
fragment	O
across	O
a	O
region	O
of	O
E1	O
that	O
had	O
a	O
high	O
degree	O
of	O
homology	O
to	O
high	O
-	O
risk	O
HPV	O
types	O
16	O
,	O
18	O
,	O
31	O
,	O
33	O
,	O
35	O
,	O
39	O
,	O
45	O
,	O
51	O
,	O
52	O
,	O
56	O
,	O
58	O
,	O
59	O
,	O
and	O
68	O
.	O

The	O

multiplex	B-HPV_Lab_Technique
PCR	I-HPV_Lab_Technique
reactions	I-HPV_Lab_Technique
were	O
run	O
on	O
a	O
Stratagene	O
Mx3000P	O
instrument	O
using	O
the	O
conditions	O
recom	O
-	O
mended	O
in	O
the	O
Quantitech	O
Multiplex	O
handbook	O
(	O
Qia	O
-	O
gen	O
)	O
.	O

Twenty	O
μl	O
reactions	O
were	O
heated	O
for	O
15	O
minutes	O
at	O
95°C	O
to	O
activate	O
the	O
amplification	O
enzyme	O
.	O

This	O
was	O
fol	O
-	O
lowed	O
by	O
40	O
cycles	O
of	O
94°C	O
for	O
60	O
seconds	O
and	O
60°C	O
for	O
90	O
seconds	O
.	O

Standard	O
curves	O
were	O
produced	O
from	O
10	O
fold	O
serial	O
dilutions	O
of	O
CaSki	O
cell	O
genomic	O
DNA	O
.	O

Caski	O
cell	O
DNA	O
was	O
used	O
as	O
a	O
positive	O
control	O
for	O
HPV16	O
and	O
HeLa	O
cell	O
genomic	O
DNA	O
was	O
used	O
as	O
the	O
HPV18	O
con	O
-	O
trol	O
.	O

All	O
samples	B-HPV_Sample_Type
were	O
first	O
tested	O
with	O
the	O
type	O
16	O
and	O

18	O
primer	O
/	O
probe	O
sets	O
.	O

Samples	B-HPV_Sample_Type
that	O
were	O
negative	O
for	O
types	O
16	O
and	O
18	O
were	O
then	O
tested	O
with	O
the	O
broad	O
-	O
spectrum	O
primer	O
/	O
probe	O
set	O
to	O
detect	O
the	O
presence	O
of	O
other	O
high	O
-	O
risk	O
HPV	O
types	O
.	O

Table	O
1	O
PCR	B-HPV_Lab_Technique
primers	O
for	O
HPV	O
testing	O

Name	O
Sequence	O
5′	O
to	O
3′	O

GAPDH	O
Forward	O
GCTCATTTGCAGGGGGGAGCC	O

GAPDH	O
Reverse	O
CTGATGATCTTGAGGCTGTTG	O

GAPDH	O
Probe	O
CY5	O
-	O
TCTGCCCCCTCTGCTGATGCCCCCATGTTCGTCATGGGA	O
–BHQ2	O

HPV	O
16	O
Forward	O
TTGCAGATCATCAAGAACACGTAGA	O

HPV	O
16	O
Reverse	O
GTAGAGATCAGTTGTCTCTGGTTGC	O

HPV	O
16	O
Probe	O
JOE	O
-	O
AATCATGCATGGAGATACACCTACATTGCATGA	O
–BHQ1	O

HPV	O
18	O
Forward	O
CAACCGAGCACGACAGGAACG	O

HPV	O
18	O
Reverse	O
TAGAAGGTCAACCGGAATTTTCAT	O

HPV	O
18	O
Probe	O
ROX	O
-	O
AATATTAAGTATGCATGGACCTAAGGCAACATTGCAA	O
–BHQ2	O

HPV	O
all	O
Forward	O
(	O
E1	O
)	O
CCTATAGTACATTTAAAAGGTG	O

HPV	O
all	O
Reverse	O
(	O
E1	O
)	O
CNTGTCCAATGCCAGGTAGATG	O

HPV	O
all	O
Probe	O
(	O
E1	O
)	O
FAM	O
-	O
AATAGTTTAAAATGTTTAAGATATAG	O
-	O
BHQ1	O

HPV	O
other	O
Forward	O
(	O
E2	O
)	O
GCATTATATTGGTATAGAACAGG	O

HPV	O
other	O
Reverse	O
(	O
E2	O
)	O
TCATTRTCASATGCCCATTGYACC	O

HPV	O
human	O
papillomavirus	O
;	O
R	O
puRine	O
(	O
A	O
or	O
T	O
)	O
;	O
S	O
Strong	O
(	O
C	O
or	O
G	O
)	O
;	O
Y	O
pYrimidine	O
(	O
C	O
or	O
T	O
)	O
.	O

High	O
-	O
risk	O
HPV	O
detection	O
by	O
conventional	O
PCR	B-HPV_Lab_Technique

Tumors	O
that	O
tested	O
positive	O
for	O
HPV	O
infection	O
by	O
qPCR	B-HPV_Lab_Technique
with	O
the	O
broad	O
spectrum	O
primer	O
/	O
probe	O
set	O
designed	O
against	O
the	O
E2	O
region	O
of	O
HPV	O
were	O
tested	O
with	O
a	O
second	O
broad	O
spectrum	O
set	O
of	O
primers	O
against	O
the	O
E1	O
region	O
of	O
HPV	O
by	O
conventional	O
PCR	B-HPV_Lab_Technique
(	O
Table	O
PCR	B-HPV_Lab_Technique
reactions	O
(	O
20	O
μl	O
)	O
were	O
prepared	O
using	O
0	O
.	O
2	O
μl	O
of	O
patient	O
template	O
DNA	O
and	O
amplified	O
with	O
Phusion	O
DNA	O
polymerase	O
(	O
Fisher	O
Scientific	O
,	O
Toronto	O
,	O
Canada	O
)	O
following	O
a	O
hotstart	O
(	O
98°C	O
for	O
30	O
sec	O
followed	O
by	O
37	O
cycles	O
of	O
98°C	O
for	O
10	O
sec	O
,	O
55°C	O
for	O
10	O
sec	O
,	O
72°C	O
for	O

30	O
sec	O
)	O
.	O

Amplified	O
products	O
were	O
resolved	O
on	O
1	O
%	O
agarose	O
gels	O
.	O

Bands	O
of	O
interest	O
were	O
extracted	O
from	O
agarose	O
gel	O
slices	O
,	O
purified	O
on	O
columns	O
(	O
Bio	O
Basic	O
,	O
Markham	O
,	O
Canada	O
)	O
and	O
sequenced	O
with	O
the	O
appropriate	O
primer	O
.	O

Results	O
were	O
used	O
to	O
query	O
the	O
Gen	O
-	O
bank	O
Database	O
to	O
identify	O
the	O
corresponding	O
HPV	O
type	O
.	O

Statistical	O
analysis	O

Statistical	O
analysis	O
was	O
performed	O
using	O
SPSS	O
with	O
the	O
exact	O
tests	O
package	O
(	O
IBM	O
,	O
Armonk	O
,	O
NY	O
)	O
.	O

For	O
all	O
analyses	O
,	O
a	O
p	O
value	O
of	O
0	O
.	O
05	O
or	O
less	O
was	O
considered	O
statistically	O
sig	O
-	O
nificant	O
.	O

Patient	O
variables	O
were	O
compared	O
using	O
the	O
Fisher	O
exact	O
test	O
.	O

Disease	O
-	O
free	O
survival	O
(	O
DFS	O
)	O
was	O
defined	O
as	O
the	O
time	O
of	O
completion	O
of	O
treatment	O
to	O
local	O
,	O
regional	O
,	O
or	O
distant	O
recurrence	O
.	O

Survival	O
curves	O
were	O
created	O
using	O
the	O
method	O
of	O
Kaplan	O
and	O
Meier	O
.	O

The	O
Cox	O
proportional	O
hazard	O
model	O
was	O
used	O
to	O
estimate	O
the	O
relative	O
hazard	O
of	O
mortality	O
or	O
recurrence	O
over	O
the	O
follow	O
-	O
up	O
period	O
and	O
to	O
perform	O
univariate	O
and	O
multivariate	O
analysis	O
.	O

Multi	O
-	O
variate	O
analysis	O
began	O
with	O
a	O
fit	O
to	O
all	O
patient	O
variables	O
,	O
followed	O
by	O
backward	O
stepwise	O
regression	O
using	O
the	O
Akaike	O
information	O
criterion	O
(	O
stepAIC	O
function	O
)	O
and	O
retention	O
of	O
variables	O
in	O
the	O
final	O
model	O
having	O
p	O
values	O
of	O
0	O
.	O
05	O
or	O
less	O
.	O

Results	O

HPV	O
-	O
16	O
presents	O
more	O
frequently	O
with	O
neck	O
metastases	O
than	O
other	O
high	O
-	O
risk	O
HPV	O
types	O

A	O
total	B-Study_Cohort
of	I-Study_Cohort
95	I-Study_Cohort
patients	I-Study_Cohort
with	I-Study_Cohort
OPSCC	I-Study_Cohort
were	I-Study_Cohort
identified	I-Study_Cohort
.	I-Study_Cohort

The	O
majority	O
of	O
patients	O
were	O
treated	O
with	O
organ	O
preservation	O
strategies	O
(	O
86	O
/	O
95	O
,	O
90	O
.	O
5	O
%	O
)	O
as	O
opposed	O
to	O
primary	O
surgery	O
(	O
9	O
/	O
95	O
,	O
9	O
.	O
5	O
%	O
)	O
(	O
Table	O
Patients	O
only	O
underwent	O
primary	O
surgery	O
if	O
they	O
refused	O
primary	O
radiation	O
(	O
2	O
)	O
,	O
had	O
gross	O
bony	O
involvement	O
on	O
imaging	O
(	O
5	O
)	O
or	O
had	O
medical	O
contra	O
-	O
indications	O
to	O
radiation	O
(	O
2	O
,	O
severe	O
scleroderma	O
)	O
.	O

Fifty	O
-	O
nine	O
patients	O
had	O
tumour	O
biopsy	B-HPV_Sample_Type
specimens	I-HPV_Sample_Type
that	O
were	O
p16	O
positive	O
.	O

Real	B-HPV_Lab_Technique
-	I-HPV_Lab_Technique
time	I-HPV_Lab_Technique
qPCR	I-HPV_Lab_Technique
for	O
high	O
-	O
risk	O
HPV	O
types	O
clearly	O
separated	O
HPV	O
-	O
positive	O
tumors	O
(	O
all	O
had	O
a	O
cycle	O
threshold	O
CT	O
<	O
30	O
)	O
and	O
negative	O
tumors	O
(	O
CT	O
>	O
35	O
)	O
.	O

Over	O
-	O
all	O
,	O
fifty	O
tumors	O
were	O
positive	O
for	O
HPV	O
,	O
including	O
45	O
positive	O
for	O
HPV	O
-	O
16	O
(	O
90	O
%	O
)	O
and	O
2	O
positive	O
for	O
HPV	O
-	O
18	O
.	O

The	O
broad	O
-	O
spectrum	O
primer	O
/	O
probe	O
set	O
detected	O
three	O
other	O
HPV	O
-	O
positive	O
tumors	O
,	O
which	O
were	O
determined	O
to	O
be	O
type	O
33	O
(	O
1	O
tumor	O
)	O
and	O
type	O
67	O
(	O
2	O
tumors	O
)	O
by	O
sequen	O
-	O
cing	O
of	O
PCR	B-HPV_Lab_Technique
products	O
.	O

The	O
identification	O
of	O
HPV	O
-	O
67	O
was	O
surprising	O
because	O
the	O
high	O
-	O
risk	O
HPV	O
-	O
67	O
sequence	O
was	O
not	O
included	O
in	O
our	O
efforts	O
to	O
design	O
broad	O
-	O
spectrum	O
primers	O
.	O

Regardless	O
,	O
sequencing	O
of	O
the	O
150	O
nt	O
product	O
was	O
highly	O
consistent	O
with	O
the	O
published	O
HPV	O
-	O
67	O
se	O
-	O
quence	O
by	O
BLAST	O
analysis	O
(	O
p	O
<	O
10	O
-	O
39	O
,	O
accession	O
D21208	O
)	O
.	O

p16	O
-	O
positivity	O
was	O
tightly	O
correlated	O
with	O
HPV	O
status	O
(	O
p	O
<	O
0	O
.	O
0001	O
,	O
Fishers	O
exact	O
test	O
)	O
,	O
further	O
supporting	O
its	O
use	O
as	O
a	O
surrogate	O
marker	O
of	O
HPV	O
infection	O
.	O

Analysis	O
of	O
patient	O
characteristics	O
and	O
HPV	O
-	O
positive	O
OPSCC	O
revealed	O
associations	O
with	O
age	O
<	O
60	O
,	O
tonsil	O
or	O
base	O
of	O
tongue	O
primary	O
site	O
,	O
and	O
minimal	O
smoking	O
history	O
(	O
p	O
<	O
0	O
.	O
05	O
,	O
Table	O
Patients	O
with	O
HPV	O
-	O
16	O
-	O
positive	O
tumors	O
were	O
compared	O
to	O
those	O
with	O
tumors	O
positive	O
for	O
other	O
high	O
-	O
risk	O
HPV	O
types	O
.	O

HPV	O
-	O
16	O
-	O
positive	O
tumors	O
were	O

Table	O
2	O
Correlation	O
of	O
HPV	O
status	O
with	O
patient	O
and	O
tumor	O
factors	O

HPV	O
human	O
papillomavirus	O
,	O
py	O
pack	O
years	O
,	O
RT	O
radiation	O
,	O
CRT	O
chemoradiation	O
.	O

Fisher	O
exact	O
test	O
.	O

significantly	O
more	O
likely	O
to	O
have	O
neck	O
metastases	O
(	O
43	O
/	O
45	O
versus	O
2	O
/	O
5	O
,	O
p	O
=	O
0	O
.	O
005	O
,	O
Table	O
One	O
of	O
two	O
HPV	O
-	O
18	O
-	O
positive	O
patients	O
and	O
one	O
of	O
two	O
HPV	O
-	O
67	O
-	O
positive	O
patients	O
had	O
lymph	O
node	O
involvement	O
.	O

The	O
sole	O
HPV	O
-	O
33	O
-	O
positive	O
patient	O
was	O
node	O
negative	O
.	O

HPV	O
-	O
positive	O
patients	O
experience	O
improved	O
survival	O

Median	O
follow	O
-	O
up	O
time	O
for	O
the	O
study	O
was	O
39	O
months	O
(	O
range	O
:	O
1	O
to	O
91	O
months	O
)	O
.	O

A	O
total	O
of	O
26	O
of	O
95	O
patients	O
(	O
27	O
%	O
)	O
recurred	O
,	O
and	O
eleven	O
(	O
42	O
%	O
)	O
of	O
these	O
patients	O
died	O

of	O
disease	O
.	O

Five	O
patients	O
died	O
of	O
other	O
causes	O
.	O

The	O
three	O
-	O
year	O
disease	O
-	O
free	O
(	O
DFS	O
)	O
and	O
overall	O
survival	O
(	O
OS	O
)	O
for	O
all	O
patients	O
was	O
75	O
%	O
and	O
85	O
%	O
,	O
respectively	O
.	O

Univariate	O
ana	O
-	O
lysis	O
identified	O
age	O
,	O
p16	O
status	O
and	O
the	O
presence	O
of	O
any	O
high	O
-	O
risk	O
HPV	O
type	O
as	O
predictors	O
of	O
disease	O
-	O
free	O
and	O
overall	O
survival	O
(	O
Table	O
and	O
Figure	O
and	O
Three	O
year	O
DFS	O
and	O
OSP	O
rates	O
for	O
patients	O
with	O
HPV	O
-	O
positive	O
versus	O
HPV	O
-	O
negative	O
tumors	O
were	O
85	O
%	O
vs	O
49	O
%	O
,	O
and	O
90	O
%	O
vs	O
65	O
%	O
;	O
respectively	O
.	O

p16	O
positivity	O
was	O
also	O
associated	O
with	O
improved	O
DFS	O
and	O
OS	O
(	O
p	O
<	O
0	O
.	O
05	O
,	O
Table	O
and	O

Table	O
3	O
Comparison	O
of	O
HPV	O
-	O
16	O
and	O
other	O
high	O
-	O
risk	O
(	O
non	O
-	O
16	O
)	O
HPV	O
types	O

HPV	O
-	O
Positive	O

HPV	O
human	O
papillomavirus	O
,	O
py	O
pack	O
years	O
,	O
RT	O
radiation	O
,	O
CRT	O
chemoradiation	O
.	O

Fisher	O
exact	O
test	O
.	O

Table	O
4	O
Univariate	O
and	O
multivariate	O
relations	O
to	O
disease	O
free	O
survival	O

DFS	O
disease	O
-	O
free	O
survival	O
,	O
OS	O
overal	O
survival	O
,	O
HR	O
hazard	O
ratio	O
,	O
CI	O
confidence	O
interval	O
,	O
py	O
pack	O
years	O
,	O
HPV	O
human	O
papillomavirus	O
.	O

*	O
CI	O
(	O
confidence	O
interval	O
)	O
by	O
Cox	O
proportional	O
hazard	O
analysis	O
.	O

*	O
*	O
Wald	O
test	O
.	O

Figure	O
and	O
Multivariate	O
analysis	O
revealed	O
high	O
-	O
risk	O
HPV	O
infection	O
as	O
the	O
only	O
independent	O
predictor	O
of	O
disease	O
-	O
free	O
and	O
overall	O
survival	O
(	O
p	O
=	O
0	O
.	O
001	O
and	O
p	O
=	O
0	O
.	O
004	O
,	O
respectively	O
,	O
Table	O
As	O
multiple	O
treatments	O
were	O
used	O
,	O
we	O
repeated	O
the	O
survival	O
analysis	O
using	O
only	O
the	O
data	O
from	O
the	O
sixty	O
-	O
two	O
patients	O
that	O
received	O
platinum	O
-	O
based	O
concurrent	O
chemoradiation	O
to	O
remove	O
this	O
potential	O
con	O
-	O
founding	O
factor	O
.	O

High	O
-	O
risk	O
HPV	O
infection	O
once	O
again	O
was	O
the	O
only	O
predictor	O
of	O
overall	O
and	O
disease	O
-	O
free	O
survival	O
(	O
p	O
<	O
0	O
.	O
005	O
,	O
data	O
not	O
shown	O
)	O
.	O

Seven	O
of	O
45	O
HPV	O
-	O
16	O
-	O
positive	O
patients	O
recurred	O
,	O
while	O
none	O
of	O
the	O
five	O
patients	O
with	O
tumors	O
due	O
to	O
non	O
-	O
16	O
high	O
-	O
risk	O
HPV	O
types	O
developed	O
a	O
recurrence	O
(	O
DFS	O
83	O
.	O
3	O
%	O
vs	O
100	O
%	O
,	O
p	O
=	O
0	O
.	O
94	O
,	O
Figure	O
No	O
difference	O
in	O
overall	O
survival	O
between	O
the	O
HPV	O
-	O
16	O
and	O
the	O
HPV	O
-	O
other	O
high	O
-	O
risk	O
group	O
was	O
detected	O
(	O
Figure	O
B	O
)	O
.	O

The	O
only	O
death	O
in	O
the	O
patients	O
with	O
non	O
-	O
16	O
HPV	O
-	O
positive	O
tumors	O
was	O
due	O
to	O
a	O
myocardial	O
infarction	O
in	O
an	O
87	O
-	O
year	O
-	O
old	O
patient	O
13	O
months	O
after	O
diag	O
-	O
nosis	O
.	O

Together	O
,	O
these	O
data	O
confirm	O
the	O
significance	O
of	O
HPV	O
as	O
a	O
prognostic	O
factor	O
in	O
OPSCC	O
,	O
and	O
suggests	O
that	O
stage	O
at	O
presentation	O
may	O
differ	O
between	O
high	O
-	O
risk	O
HPV	O
types	O
.	O

Discussion	O

Recent	O
studies	O
have	O
clearly	O
described	O
the	O
current	O
epi	O
-	O
demic	O
of	O
HPV	O
-	O
positive	O
oropharyngeal	O
squamous	O
cell	O
car	O
-	O
cinoma	O
(	O
OPSCC	O
)	O
in	O
North	B-Study_Location
America	I-Study_Location
and	O
beyond	O
Using	O
tumors	O
from	O
patients	O
from	O
three	O
American	O
popu	O
-	O
lation	O
based	O
cancer	O
registries	O
in	O
the	O
Surveillance	O
,	O
Epi	O
-	O
demiology	O
and	O
End	O
Results	O
(	O
SEER	O
)	O
program	O
,	O
Chaturvedi	O
et	O
al	O
conclusively	O
demonstrated	O
that	O
HPV	O
-	O
positive	O
OPSCC	O
has	O
increased	O
markedly	O
(	O
225	O
%	O
)	O
over	O
the	O
last	O
three	O
decades	O
.	O

Improved	O
survival	O
for	O
patients	O
with	O
HPV	O
-	O
positive	O
OPSCC	O
was	O
reported	O
and	O
our	O
results	O
agree	O
with	O
this	O
finding	O
.	O

Patients	O
tend	O
to	O
be	O
younger	O
,	O
non	O
-	O
smokers	O
,	O
and	O
non	O
-	O
drinkers	O
with	O
low	O
rates	O
of	O
comorbid	O
illness	O
The	O
observed	O
high	O
cure	O
rates	O
in	O
this	O
high	O
func	O
-	O
tioning	O
cohort	O
of	O
younger	O
patients	O
has	O
led	O
to	O
an	O
increased	O
emphasis	O
on	O
post	O
-	O
treatment	O
quality	O
of	O
life	O
,	O
as	O
treatment	O
side	O
effects	O
will	O
potentially	O
need	O
to	O
be	O
endured	O
for	O
decades	O
.	O

Consequently	O
,	O
several	O
studies	O
have	O
been	O
initiated	O
with	O
the	O
goal	O
of	O
the	O
long	O
-	O
term	O
sequelae	O
of	O
ther	O
-	O
apy	O
for	O
patients	O
with	O
HPV	O
-	O
positive	O
OPSCC	O
,	O
such	O
as	O
the	O
substitution	O
of	O
cetuximab	O
for	O
cisplatin	O
in	O
RTOG	O
-	O
1016	O
.	O

However	O
,	O
a	O
fraction	O
of	O
these	O
patients	O
still	O
relapse	O
and	O
suc	O
-	O
cumb	O
to	O
disease	O
following	O
conventional	O
therapy	O
.	O

Ang	O
et	O
al	O

[	O
]	O
demonstrated	O
that	O
21	O
.	O
2	O
%	O
of	O
patients	O
with	O
HPV	O
-	O
positive	O
tumors	O
relapsed	O
within	O
3	O
years	O
,	O
with	O
13	O
.	O
6	O
%	O
of	O
these	O
cases	O
due	O
to	O
locoregional	O
recurrence	O
,	O
and	O
8	O
.	O
7	O
%	O
due	O
to	O
the	O
devel	O
-	O
opment	O
of	O
distant	O
metastases	O
.	O

The	O
biological	O
reasons	O
for	O
this	O
difference	O
in	O
treatment	O
effectiveness	O
are	O
poorly	O
under	O
-	O
stood	O
.	O

A	O
partial	O
explanation	O
may	O
be	O
the	O
specific	O
HPV	O
type	O
implicated	O
.	O

In	O
cervical	O
cancer	O
,	O
HPV	O
types	O
18	O
and	O
58	O
are	O
associated	O
with	O
a	O
poorer	O
prognosis	O
,	O
while	O
HPV	O
-	O
31	O
portends	O
improved	O
survival	O
compared	O
with	O
HPV	O
-	O
16	O
To	O
date	O
only	O
one	O
study	O
has	O
demonstrated	O
investigated	O
a	O
differential	O
response	O
or	O
clinical	O
presentation	O
by	O
HPV	O
type	O
in	O
head	O
and	O
neck	O
cancer	O
.	O

Rautava	O
et	O
al	O
.	O
,	O
retrospectively	O
analyzed	O
106	O
patients	O
with	O
tumors	O
from	O
multiple	O
head	O
and	O
neck	O
sites	O
in	O
-	O
cluding	O
31	O
oropharyngeal	O
patients	O
]	O
.	O

HPV	O
genotyping	O
was	O
performed	O
with	O
a	O
Luminex	O
based	O
MultimetrixW	O
geno	O
-	O
typing	O
kit	O
.	O

In	O
contrast	O
with	O
most	O
studies	O
,	O
they	O
found	O
a	O
very	O

high	O
rate	O
of	O
infection	O
in	O
non	O
-	O
oropharyngeal	O
sites	O
including	O
the	O
oral	O
cavity	O
(	O
76	O
%	O
)	O
and	O
larynx	O
(	O
40	O
%	O
)	O
,	O
as	O
well	O
as	O
very	O
high	O
rate	O
of	O
co	O
-	O
infection	O
(	O
44	O
%	O
)	O
and	O
the	O
presence	O
of	O
low	O
-	O
risk	O
sub	O
-	O
types	O
6	O
and	O
11	O
(	O
20	O
%	O
)	O
[	O
,	O
]	O
.	O

HPV	O
was	O
not	O
found	O
to	O
be	O
pre	O
-	O
dictive	O
of	O
survival	O
and	O
there	O
was	O
no	O
difference	O
in	O
outcome	O
based	O
on	O
HPV	O
type	O

Although	O
limited	O
conclusions	O
can	O
be	O
drawn	O
given	O
the	O
small	O
numbers	O
of	O
HPV	O
types	O
other	O
than	O
HPV	O
-	O
16	O
in	O
our	O
cohort	O
,	O
our	O
data	O
suggests	O
that	O
HPV	O
-	O
16	O
cancers	O
may	O
present	O
more	O
frequently	O
with	O
lymph	O
node	O
metastases	O
and	O
may	O
have	O
a	O
poorer	O
outcome	O
compared	O
with	O
non	O
-	O
16	O
high	O
-	O
risk	O
HPV	O
types	O
.	O

Given	O
the	O
low	O
frequency	O
of	O
HPV	O
-	O
positive	O
OPSCC	O
presentations	O
that	O
are	O
not	O
due	O
to	O
HPV	O
-	O
16	O
,	O
a	O
very	O
large	O
multi	O
-	O
institutional	O
series	O
with	O
HPV	O
genotyping	O
would	O
need	O
to	O
be	O
assembled	O
in	O
order	O
to	O
answer	O
this	O
ques	O
-	O
tion	O
definitively	O
.	O

A	O
tremendous	O
step	O
forward	O
in	O
the	O
battle	O
against	O
the	O
multiple	O
cancers	O
caused	O
by	O
HPV	O
is	O
the	O
implementation	O
of	O

HPV	O
vaccination	O
programs	O
worldwide	O
.	O

The	O
quadrivalent	O
HPV	O
vaccine	O
is	O
highly	O
effective	O
in	O
preventing	O
benign	O
and	O
precancerous	O
lesion	O
lesions	O
due	O
to	O
HPV	O
types	O
6	O
,	O
11	O
,	O
16	O
and	O
18	O
including	O
cervical	O
and	O
anal	O
dysplasia	O
[	O
]	O
.	O

Due	O
to	O
the	O
significant	O
lag	O
time	O
between	O
infection	O
and	O
the	O
devel	O
-	O
opment	O
of	O
malignancy	O
,	O
it	O
will	O
take	O
decades	O
to	O
determine	O
if	O
these	O
vaccines	O
are	O
effective	O
in	O
preventing	O
anogenital	O
and	O
head	O
and	O
neck	O
cancers	O
.	O

Indeed	O
,	O
most	O
individuals	O
develop	O
HPV	O
infection	O
in	O
their	O
teens	O
and	O
twenties	O
[	O
]	O
,	O
however	O
the	O
average	O
age	O
of	O
diagnosis	O
of	O
HPV	O
-	O
positive	O
patients	O
in	O
our	O
study	O
was	O
58	O
years	O
(	O
range	O
,	O
43–86	O
)	O
.	O

Due	O
to	O
this	O
signifi	O
-	O
cant	O
time	O
gap	O
as	O
well	O
as	O
low	O
rates	O
of	O
use	O
of	O
this	O
vaccine	O
in	O
both	O
males	O
and	O
females	O
,	O
the	O
burden	O
of	O
HPV	O
-	O
related	O
can	O
-	O
cers	O
will	O
be	O
an	O
important	O
clinical	O
problem	O
for	O
the	O
foresee	O
-	O
able	O
future	O
.	O

HPV	O
-	O
positive	O
cancers	O
are	O
fundamentally	O
distinct	O
from	O
traditional	O
tobacco	O
and	O
alcohol	O
related	O
cancers	O
Viral	O
oncogenes	O
E6	O
and	O
E7	O
cause	O
the	O
degradation	O
of	O
wild	O
-	O
type	O
p53	O
and	O
pRb	O
,	O
respectively	O
,	O
while	O
p16	O
is	O
overexpressed	O
.	O

This	O
is	O
in	O
contrast	O
to	O
frequent	O
mutations	O
of	O
p53	O
and	O
loss	O
of	O
p16	O
seen	O
in	O
conventional	O
head	O
and	O
neck	O
cancer	O
The	O
differences	O
between	O
HPV	O
-	O
positive	O
and	O
conventional	O
head	O
and	O
neck	O
cancers	O
was	O
further	O
highlighted	O
in	O
two	O
landmark	O
papers	O
by	O
Stransky	O
and	O
Agrawal	O
that	O
reported	O
large	O
-	O
scale	O
whole	O
exome	O
sequencing	O
of	O
head	O
and	O
neck	O
cancers	O
[	O
These	O
studies	O
revealed	O
approximately	O
a	O
two	O
to	O
four	O
-	O
fold	O
increase	O
in	O
number	O
of	O
mutations	O
in	O
HPV	O
-	O
negative	O
compared	O
with	O
HPV	O
-	O
positive	O
cancers	O
and	O
confirmed	O
the	O
differences	O
in	O

p53	O
and	O
p16	O
outlined	O
above	O
.	O

Despite	O
these	O
differences	O
,	O
there	O
were	O
significant	O
overlaps	O
in	O
the	O
mutational	O
profiles	O
of	O
the	O
two	O
cancer	O
types	O
,	O
including	O
mutations	O
in	O
the	O
NOTCH	O
receptors	O
(	O
NOTCH1	O
-	O
3	O
)	O
,	O
HRAS	O
,	O
and	O
PIK3CA	O
that	O
were	O
seen	O
in	O
both	O
HPV	O
-	O
positive	O
and	O
negative	O
disease	O
.	O

Potentially	O
,	O
high	O
-	O
throughput	O
technologies	O
including	O
expression	O
microar	O
-	O
rays	O
,	O
RNA	O
-	O
seq	O
,	O
and	O
exome	O
sequencing	O
of	O
large	O
cohorts	O
of	O
HPV	O
-	O
positive	O
OPSCC	O
can	O
identify	O
biomarkers	O
of	O
local	O
,	O
re	O
-	O
gional	O
and	O
distant	O
relapse	O
as	O
well	O
as	O
biological	O
differences	O
between	O
cancers	O
due	O
to	O
different	O
HPV	O
types	O
.	O

Patients	O
at	O
high	O
-	O
risk	O
of	O
failure	O
could	O
undergo	O
treatment	O
intensifica	O
-	O
tion	O
with	O
the	O
goal	O
of	O
increasing	O
survival	O
,	O
while	O
low	O
-	O
risk	O
patients	O
could	O
have	O
their	O
treatment	O
de	O
-	O
intensified	O
in	O
order	O
to	O
optimize	O
post	O
-	O
treatment	O
quality	O
of	O
life	O
.	O

This	O
would	O
be	O
a	O
significant	O
step	O
towards	O
customized	O
care	O
for	O
patients	O
with	O
HPV	O
-	O
positive	O
HNSCC	O
.	O

Conclusions	O

HPV	O
infection	O
is	O
the	O
etiologic	O
factor	O
for	O
a	O
significant	O
proportion	O
of	O
OPSCC	O
in	O
Southwestern	B-Study_Location
Ontario	I-Study_Location
as	O
has	O
been	O
observed	O
worldwide	O
.	O

The	O
majority	O
of	O
cases	O
are	O
at	O
-	O
tributable	O
to	O
HPV	O
-	O
16	O
,	O
while	O
other	O
high	O
-	O
risk	O
subtypes	O
are	O
responsible	O
for	O
the	O
remainder	O
.	O

HPV	O
-	O
16	O
-	O
positive	O
OPSCC	O
may	O
present	O
at	O
a	O
more	O
advanced	O
stage	O
than	O
those	O
due	O
to	O
other	O
high	O
-	O
risk	O
HPV	O
types	O
.	O

Larger	O
studies	O
are	O
required	O

to	O
confirm	O
this	O
observation	O
and	O
determine	O
if	O
different	O
HPV	O
types	O
influence	O
prognosis	O
.	O

Competing	O
interest	O

This	O
study	O
was	O
supported	O
by	O
an	O
investigator	O
initiated	O
grant	O
from	O
Merck	O
Canada	O
,	O
Inc	O
.	O

The	O
authors	O
have	O
no	O
other	O
disclosures	O
.	O

Authors’	O
contribution	O

This	O
project	O
has	O
been	O
a	O
coordinated	O
effort	O
designed	O
by	O
the	O
London	O
Health	O
Sciences	O
Centre	O
Head	O
and	O
Neck	O
multidisciplinary	O
team	O
.	O

Specifically	O
,	O
medical	O
oncologists	O
(	O
EW	O
,	O
SK	O
,	O
SE	O
)	O
,	O
radiation	O
oncologists	O
(	O
DP	O
,	O
NR	O
,	O
VV	O
,	O
JAH	O
)	O
,	O
head	O
and	O
neck	O
surgeons	O
(	O
AN	O
,	O
KF	O
,	O
JY	O
,	O
JF	O
,	O
SD	O
)	O
and	O
translational	O
scientists	O
(	O
AN	O
,	O
JSM	O
,	O
JK	O
,	O
JWB	O
)	O
planned	O
this	O
study	O
together	O
from	O
its	O
initiation	O
.	O

Dr	O
.	O
Marina	O
Salvadori	O
(	O
MI	O
)	O
,	O
an	O
HPV	O
and	O
vaccine	O
expert	O
,	O
was	O
also	O
involved	O
with	O
the	O
study	O
design	O
.	O

Pathologists	O
(	O
BW	O
and	O
KK	O
)	O
were	O
responsible	O
for	O
screening	O
all	O
specimens	B-HPV_Sample_Type
for	O
the	O
presence	O
of	O
tumor	O
.	O

As	O
this	O
study	O
involved	O
a	O
large	O
retrospective	O
chart	O
review	O
,	O
specimen	B-HPV_Sample_Type
retrieval	O
,	O
DNA	O
extraction	O
,	O
and	O
HPV	O
testing	O
multiple	O
trainees	O
were	O
involved	O
.	O

Specifically	O
,	O
patient	O
data	O
was	O
extracted	O
by	O
SSD	O
,	O
CC	O
,	O
JB	O
,	O
and	O
DNA	O
was	O
extracted	O
by	O
AN	O
and	O
JWB	O
.	O

All	O
HPV	O
testing	O
was	O
done	O
by	O
the	O
senior	O
author	O
JWB	O
.	O

The	O
manuscript	O
was	O
written	O
by	O
AN	O
and	O
JWB	O
and	O
critically	O
revised	O
by	O
all	O
authors	O
.	O

All	O
authors	O
read	O
and	O
approved	O
the	O
final	O
manuscript	O
.	O

Funding	O

This	O
study	O
was	O
supported	O
by	O
a	O
research	O
grant	O
from	O
Merck	O
Canada	O
Inc	O
.	O

This	O
material	O
has	O
never	O
been	O
published	O
and	O
is	O
not	O
currently	O
under	O
evaluation	O
in	O
any	O
other	O
peer	O
-	O
reviewed	O
publication	O
.	O

Author	O
details	O

1Department	O
of	O
Otolaryngology	O
,	O
Head	O
&	O
Neck	O
Surgery	O
,	O
The	O
University	O
of	O
Western	O
Ontario	O
,	O
Room	O
B3	O
-	O
431A	O
,	O
800	O
Commissioners	O
Road	O
East	O
,	O
London	O
N6A	O
5W9	O
,	O
Ontario	O
,	O
Canada	O
.	O

2London	O
Regional	O
Cancer	O
Program	O
,	O
London	O
,	O
Ontario	O
,	O
Canada	O
.	O

3Lawson	O
Health	O
Research	O
Institute	O
,	O
London	O
Ontario	O
,	O
Canada	O
.	O

4Department	O
of	O
Oncology	O
,	O
The	O
University	O
of	O
Western	O
Ontario	O
,	O
London	O
Ontario	O
,	O
Canada	O
.	O

5Department	O
of	O
Pathology	O
,	O
The	O
University	O
of	O
Western	O
Ontario	O
,	O
London	O
,	O
Ontario	O
,	O
Canada	O
.	O

6Department	O
of	O
Paediatrics	O
,	O
Infectious	O
Disease	O
Division	O
,	O
The	O
University	O
of	O
Western	O
Ontario	O
,	O
London	O
,	O
Ontario	O
,	O
Canada	O
.	O

7Department	O
of	O
Microbiology	O
and	O
Immunology	O
,	O
The	O
University	O
of	O
Western	O
Ontario	O
,	O
London	O
,	O
Ontario	O
,	O
Canada	O
.	O

Received	O
:	O
19	O
November	O
2012	O
Accepted	O
:	O
6	O
January	O
2013	O

Published	O
:	O
1	O
February	O
2013	O

